Leinco Technologies

FCM Staining Buffer (BSA) (10X)

Product Code:
 
LEI-F1175
Product Group:
 
Biological Buffers
Regulatory Status:
 
RUO
Storage:
 
Store at 2-8°C. Do Not Freeze
 

No additional charges, what you see is what you pay! *

CodeSizePrice
LEI-F1175-CustomCustomEnquire
Quantity:
LEI-F1175-1L1 L£291.00
Quantity:
Prices exclude any Taxes / VAT
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: US.
Typical lead time: 14-21 working days.
Contact us for more accurate information.
  • Further Information
  • References
  • Show All

Further Information

Long Description:
This FCM or BSA Stain Buffer can be used for the immunofluorescent staining of single-cell suspensions prepared from either lymphoid tissues, bone marrow, peripheral blood, or cultured cells. This buffer is also useful for applications using fluorescent reagents as well as for the suspension, washing, and storage of cells destined for flow cytometric analysis (or fluorescence microscopy). Application: FCM Stain Buffer (BSA) is useful for staining cells with biotinylated antibodies and fluorochrome- conjugated avidins because this staining medium contains no biotin. When present in staining media, free biotin can interfere with the binding of fluorescent-avidins to biotinylated antibodies that have complexed with their cognate, cell-associated antigens. Moreover, free biotin can bind to cells and contribute to an increase in the non-specific, background staining of cells that are exposed to fluorochrome-conjugated avidins. As such, FCM Stain Buffer (BSA) is designed to maintain cell viability and maximize fluorescence signal intensities generated by pH-sensitive fluorochromes, such as FITC. The FCM Stain Buffer (BSA) should be used at a 1X concentration.

References

1. Soh, Kah Teong et al. ?Methodological considerations for the high sensitivity detection of multiple myeloma measurable residual disease.? Cytometry. Part B, Clinical cytometry vol. 98,2 (2020): 161-173. doi:10.1002/cyto.b.21862 Link